#BIO22 survey: The E100 assess the Nasdaq winter that is freezing out biotech. But hiring remains a top priority
There’s no denying the nature of the sea change biopharma is undergoing today as the IPO window remains largely slammed shut. And the message has clearly sunk in among biotech CEOs.
Surveying our E100 group offered plenty of evidence that the upbeat sentiment of the past 6 years took a beating during H1. And the realists wonder just how long this Nasdaq winter will last.
But there are a lot of white-hot issues in the industry right now, from the Aduhelm fiasco that preceded Michel Vounatsos’ departure from the company, to debates over the accelerated approval process and trends at the FDA. Let’s take a look at the sentiment out there.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
